Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Myriad Genetics Q3 2026 Results: Net Loss of $43.9M, Loss Widens

Myriad Genetics reported a revenue decline to $202.7 million for the third quarter of 2026, resulting in a net loss of $43.9 million. While the company significantly reduced its nine-month operating loss compared to the prior year—which was impacted by a $316.7 million impairment charge—it continues to face challenges with rising sales and marketing expenses.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue202.7205.7
Gross profit137.7143.8
Profit before tax-43.6-26.2
Net income-43.9-27.4
EPS (diluted, $ a share)$-0.46$-0.29

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-1.5%
Gross margin67.9%
Operating margin-19.7%
Source

10-Q filed with the SEC, NASDAQ: MYGN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Myriad Genetics Inc: key numbers

Share price
$5.57Close, Nov 16
Market cap
$534M
Shares outstanding
95.92MLatest SEC cover page
Sector
Life Sciences
Industry
In Vitro & In Vivo Diagnostic SubstancesSIC 2835

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Myriad Genetics Inc

All →
4:02 PM ET 8-K
Stock Plan Amendment

Myriad Genetics Stock Plan Amendment

Myriad Genetics approved one-time retention stock option awards for its executive leadership team, including the CFO, COO, and CSO. The awards are granted under the 2026 Equity Incentive Plan and will vest fully on the third anniversary of the grant date to ensure leadership continuity during operational efficiency initiatives.

9:07 AM ET 8-K
Cybersecurity Incident

Myriad Genetics Cybersecurity Incident

Myriad Genetics detected unauthorized access to its IT network on November 2, 2026, leading to a temporary suspension of testing operations and order management systems. The company has engaged external experts to investigate the scope of the breach, including potential access to patient records, though most systems have since returned to normal operations. Management currently believes the incident will not have a material adverse effect on the business.

4:09 PM ET 8-K
Financial Results

Myriad Genetics Financial Results

Myriad Genetics reported Q3 2026 revenue of $202.7 million and raised its full-year revenue guidance mid-point. The company also highlighted a definitive agreement to sell its Prenatal Health business to Labcorp for $210 million in cash to focus on its Cancer Care Continuum and Mental Health segments.

Counterparty
Labcorp

“We have made meaningful progress on our path to accelerate profitable growth and strengthen the company’s financial profile. Our third quarter 2026 financial results exceeded our expectations, led by our on-going focus on the Cancer Care Continuum (CCC).”

Sam Raha, President and CEO, Myriad Genetics

“The sale of our Prenatal Health business is a decisive step to support our strategic intent to increase profitable growth by focusing on the Cancer Care Continuum including screening, treatment selection and monitoring along with remission surveillance.”

Sam Raha, President and CEO, Myriad Genetics
8:37 AM ET 8-K
Divestiture

Myriad Genetics Divestiture to Laboratory Corporation of America for $210M

Myriad Genetics has entered into a definitive agreement to sell its prenatal health testing business, including the Foresight, Prequel, and SneakPeek tests, to Labcorp for $210 million in cash. The divestiture is part of a strategic review to focus on the company's cancer care continuum and is expected to close by early 2027.

Value
$210M
Counterparty
Laboratory Corporation of America
4:16 PM ET 8-K
Executive Compensation

Myriad Genetics Executive Compensation

Myriad Genetics entered into a separation agreement with former Chief Commercial Officer Brian Donnelly following his departure on September 21, 2026. Mr. Donnelly will receive a lump sum severance payment of approximately $1.32 million and accelerated vesting of outstanding time-based and performance-based equity awards for a two-year period. The agreement includes customary non-solicitation and non-disparagement covenants and a release of claims against the company.

Counterparty
Brian Donnelly

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.